U.S. Markets close in 6 hrs 9 mins

InVivo Therapeutics Holdings Corp. (NVIV)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.325+0.025 (+1.923%)
As of 9:48AM EDT. Market open.
People also watch
AVXLCURONCSADXSBCLI
Full screen
Previous Close1.300
Open1.350
Bid1.300 x 7700
Ask1.350 x 11100
Day's Range1.300 - 1.350
52 Week Range1.100 - 6.970
Volume6,829
Avg. Volume408,800
Market Cap45.32M
Beta3.20
PE Ratio (TTM)-1.73
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • American City Business Journals21 days ago

    InVivo slashes staff and ousts science chief

    Cambridge-based InVivo Therapeutics said on Monday said that it plans to lay off more than a third of its workforce and terminate its chief scientific officer. The latest news comes one month after the company reported that a third patient had died in a trial of its experimental spinal cord injury treatment. In a separate federal filing, the company said it had notified its chief scientific officer, Thomas Ulich, that he will be terminated effective on Wednesday.

  • Associated Presslast month

    InVivo reports 2Q loss

    The Cambridge, Massachusetts-based company said it had a loss of 20 cents per share. The company's shares closed at $1.80. A year ago, they were trading at $6.36. _____ This story was generated by Automated ...

  • American City Business Journals2 months ago

    InVivo halts trial of spine injury treatment after third patient dies

    InVivo Therapeutics said Monday it has halted a trial of its spinal cord injury treatment after a third patient died, sending shares of the Cambridge company plummeting. InVivo (NVIV) announced that it would temporarily stop enrolling patients in the trial of its Neuro-Spinal Scaffold, a biodegradable device invented in part by MIT professor Bob Langer designed to help patients heal after spinal cord injuries.